NCT05590793 2025-09-09
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen
Phase 3 Completed
Clinical Trials
13 trialsNCT01673984 2025-05-23
GREAT
Ipsen
Phase 4 Terminated
NCT01753297 2020-12-09
PRIORITI
Ipsen
Phase 4 Completed
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT01715129 2019-12-09
DKP 3M SC
Ipsen
Phase 3 Completed
NCT00415246 2019-11-22
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
Ipsen
Phase 3 Terminated
NCT00444639 2019-11-22
Study to Assess the Non-inferiority of PamorelinĀ® 11,25mg SC Injected Versus PamorelinĀ® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
Ipsen
Phase 2 Terminated
NCT01374087 2019-09-18
ANABRAQ
Ipsen
Phase 2 Terminated
NCT01257425 2019-02-08
PAMIS
Ipsen
Phase 2 Completed
NCT01020448 2019-01-30
Triptocare
Ipsen
Phase 3 Completed
NCT01656161 2015-09-15
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed
NCT00751790 2014-07-25
Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed
NCT01161563 2013-09-06
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Watson Pharmaceuticals
Phase 4 Completed